| Goins et al.(1414 Goins KM, Kitzmann AS, Greiner MA, Kwon YH, Alward WLM, Ledolter J, et al. Boston Type 1 keratroprosthesis: visual outcomes, device retention, and complications. Cornea. 2016; 35(9):1165-74.) |
85.3 (64/75) |
Retroprosthetic membrane Maculopathy - 34.7 |
Final: 57.3 (43/75) |
| Aravena et al.(1515 Aravena C, Yu F, Aldave AJ. Long-term visual outcomes, complications, and retention of the boston type i keratoprosthesis. Cornea. 2018;37(1):3-10.) |
74.3 (55/74) |
Retroprosthetic membrane - 51.7 |
Mean: 86
(50/58)
Final: 22 (18/50)
|
| Muzychuk et al.(1616 Muzychuk AK, Robert MC, Dao S, Harissi-Dagher M. Boston Keratoprosthesis type 1: a randomized controlled trial of fresh versus frozen corneal donor carriers with long-term follow-up. Ophthalmology. 2017;124(1):20-6. [) |
24 months: (37/37)
60 months: 96 (25/26)
|
Glaucoma - 65
Retroprosthetic membrane - 47
|
2 years: 57 (21/37)
Final: 46 (12/26)
|
| Rudnisky et al.(1717 Rudnisky CJ, Belin MW, Guo R, Ciolino JB, Dohlman CH, Aquavella J, et al.; Boston Type 1 Keratoprosthesis Study Group. Visual acuity outcomes of the boston keratoprosthesis type 1: multicenter study results. Am J Ophthalmol. 2016;162:89-98.e1.) |
93 (279/300) |
NI |
Mean: 84.7 (254/300)
Final: 80.9 (241/300)
|
| Ang et al.(1818 Ang M, Man R, Fenwick E, Lamoureux E, Wilkins M. Impact of type I Boston keratoprosthesis implantation on vision-related quality of life. Br J Ophthalmol. 2018;102(7):878-81.) |
90 (59/66) |
NI |
3,5 years: 100 (66/66)
5-year estimative: 60 (40/66)
|
| Driver et al.(1919 Driver TH, Aravena C, Duong HN, Christenbury JG, Yu F, Basak SK, et al. Outcomes of the Boston type I keratoprosthesis as the primary penetrating corneal procedure. Cornea. 2018;37(11):1400-7.) |
90 (207/231) |
Retroprosthetic membrane - 40 e 51
Persistent epithelial defect - 37 e 24
|
1 year: 69.05
(145/210)
Final: 41.07 (23/56)
|
| Lee et al.(2020 Lee R, Khoueir Z, Tsikata E, Chodosh J, Dohlman CH, Chen TC. Long-term visual outcomes and complications of Boston keratoprosthesis type ii implantation. Ophthalmology. 2017;124(1):27-35.) |
50 (24/48) |
Retroprosthetic membrane - 60.4 |
Mean: 91.7 (44/48)
Final: 37.5 (18/48)
|
| Basu et al.(2121 Basu S, Serna-Ojeda JC, Senthil S, Pappuru RR, Bagga B, Sangwan V. The Aurolab Keratoprosthesis (KPro) versus the Boston Type I Kpro: 5-year clinical outcomes in 134 cases of bilateral corneal blindness. Am J Ophthalmol. 2019;205:175-83.) |
Boston type I KPro: 70.5 (55/78)
Aurolab KPro: 62.5 (35/56)
|
Glaucoma - 28.4 |
Boston type I, mean: 87.3 (68/78)
Final: 26.92 (21/78)
Aurolab KPro, mean: 90 (49/56)
Final: 26.78 (15/56)
|
| Venugopal et al.(2222 Venugopal A, Rathi H, Rengappa R, Ravindran M, Raman R. Outcomes after auro keratoprosthesis implantation: a low-cost design based on the boston keratoprosthesis. Cornea. 2016;35(10):1285-8.) |
73.3 (11/15) |
Retroprosthetic membrane - 46.7
Graft infection - 26.7
|
Final: 60 (9/15) |
| Charoenrook et al.(2323 Charoenrook V, Michael R, de la Paz MF, Temprano J, Barraquer RI. Comparison of long-term results between osteo-odontokeratoprosthesis and tibial bone keratoprosthesis. Ocul Surf. 2018; 16(2):259-64.) |
OOKP: 67 (97/145) Tibial bone keratoprothesis: (61/113) |
Retinal detachment - 15 e 16
Retroprosthetic membrane - 3 e 23
|
NI |
| Duignan et al.(2424 Duignan ES, Ní Dhubhghaill S, Malone C, Power W. Long-term visual acuity, retention and complications observed with the type-I and type-II Boston keratoprostheses in an Irish population. Br J Ophthalmol. 2016;100(8):1093-7.) |
Boston type I KPro: 85 (29/34)
Boston type II KPro: 67 (2/3)
|
Retroprosthetic membrane - 52.9
Glaucoma - 17.6
|
Final: 82.4 (28/34) |
Thumbnail
